Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: jake burns who wrote (658)	6/30/1998 11:41:00 AM
From: Robert Knight	Read Replies (1) \| Respond to of 1510

I would have to defer on that question. I do know that the conference is emphasizing the immune based therapies. Remune is the farthest along and would be the first to market IMO. Thats why if the news from Geneva is substantial the investment community should stand up and take notice. If you read any of the commentary out of Geneva, all the top dogs are saying that we are 10 years away from a vaccine. So improving the lives of people who have the virus and suppressing it seems to be the current line of thought. One could deduce that the scheduling of IMNR's presentation portends to something substantial. Lets hope so.... Robert